Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2018
December 2018, Vol 9, No 4
December 2018, Vol 9, No 4
CAR T-Cell Therapy: Can We Afford the Cure?
By
Meg Barbor, MPH
Value-Based Care
,
Economics & Value
December 2018, Vol 9, No 4
Chicago, IL—So far, 2 chimeric antigen receptor (CAR) T-cell therapies have been approved by the FDA for some types of relapsed or refractory lymphoma and leukemia. Although CAR T-cell therapy has shown promise in many patients who have run out of standard treatment options, it is incredibly resource-intense: the complexities of its administration require an interdisciplinary approach for success, the side effects can be severe, and its high cost can reach upward of $1 million per course of treatment.
Read Article
Addressing Financial Toxicity Through Systematic Change
By
Meg Barbor, MPH
Value-Based Care
,
Economics & Value
December 2018, Vol 9, No 4
Although the cost of care can have severe effects on patients with cancer and their families, oncologists rarely address financial toxicity, according to Hanna K. Sanoff, MD, MPH, Medical Director, University of North Carolina (UNC) NC Cancer Hospital Clinics.
Read Article
Do No Financial Harm: How to Improve Cost Transparency in Cancer Care
Economics & Value
,
Value-Based Care
December 2018, Vol 9, No 4
Read Article
Online First
Udenyca, Second Biosimilar to Neulasta, FDA-Approved to Reduce Risk for Infection in Patients with Nonmyeloid Malignancies
FDA Approvals, News & Updates
,
Biosimilars
December 2018, Vol 9, No 4
On November 2, 2018, the FDA approved pegfilgrastim-cbqv (Udenyca; Coherus BioSciences), as the second biosimilar to pegfilgrastim (Neulasta), to reduce the risk for infection in patients with nonmyeloid malignancies who receive myelosuppressive chemotherapy, which may result in febrile neutropenia.
Read Article
Online First
Talzenna Approved for HER2-Negative, Locally Advanced Breast Cancer with Germline BRCA Mutations
Breast Cancer
,
FDA Approvals, News & Updates
,
Solid Tumors
December 2018, Vol 9, No 4
On October 16, 2018, the FDA approved talazoparib (Talzenna; Pfizer), a poly (ADP-ribose) polymerase (PARP) inhibitor, for the treatment of patients with HER2-negative, locally advanced or metastatic breast cancer and deleterious or suspected deleterious germline
BRCA
mutation, as identified by an FDA-approved test.
Read Article
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Perioperative Nivolumab Extends Event-Free Survival in Resectable NSCLC
William King
2.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
3.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma